 RAMSEY, N.J. and BOCA RATON, Fla., Dec. 16, 2020 GLOBE NEWSWIRE -- ADMA Biologics, Inc. Nasdaq: ADMA, an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock. The record date for such dividend distribution is December 30, 2020. The rights plan expires, without any further action being required to be taken by ADMAs Board of Directors, on December 15, 2021. 